Tags: Andreas Abel ThesisGood Thesis Statements On The RenaissanceBa In Creative WritingEducation System In Cambodia EssayEssay Structure ActivitiesEmbalming ThesisFight Club Consumerism ThesisMlk I Have A Dream Thesis StatementEssay Peace NonviolenceAp Biology Cell Respiration Essay
Their boss Campbell was not taking their staff in confidence he should coordinate Weaver before accepting Scully’s invitation to present distribution review. Donna missed her first chance by misunderstanding the situation.
Professor Donna Davies is Professor of Respiratory Cell and Molecular Biology, within Medicine at the University of Southampton.
Professor Donna Davies (nee Harrison) was awarded a Personal Chair in Respiratory Cell and Molecular Biology in 2004.
BSc, Biochemistry, University of Wales (1975)Ph D, Ribulose 1,5 Bisphosphate Carboxylase from Microorganisms, University of Wales (1979) Post-Doctoral Research Associate, Nuffield Dept.
of Clinical Biochemistry, University of Oxford (1979-1982)R. Lawrence Fellow of The British Diabetic Association, Nuffield Dept.
She has pioneered the use of in vitro models allowing the use of methodologies that could not be used ethically in vivo.
Notable discoveries from her work include demonstration of defective epithelial barrier function in asthma and identification of a lesion in innate immune response of asthmatic epithelial cells that may explain why the common cold virus causes exacerbations of asthma.
She moved to the CRC Wessex Medical Oncology Unit at the University of Southampton in 1985, before she joined the Respiratory Group through the award of a University of Southampton Senior Research Fellowship and then a Readership.
Professor Davies leads a multidisciplinary group that studies mechanisms of respiratory diseases, especially in areas of unmet medical need such as severe, corticosteroid refractory asthma and virus-induced exacerbations of asthma and COPD.
This has led to a patent for the use of inhaled interferon-beta (IFN-β) for treatment of virus-induced exacerbations of asthma and COPD.
This novel therapeutic is currently in Phase II clinical trials having been developed by ‘Synairgen’, a University of Southampton spin-out company that she co-founded with Stephen Holgate and Ratko Djukanovic in 2003.